Table 2. MicroRNAs with potential value as biomarkers in MPM patient samples.
| MicroRNA | Expression change in tumours or in blood | Number of samples tested | Reference(s) |
|---|---|---|---|
| miR-29c-5p | Higher expression associated with good prognosis | 129 MPM | (18) |
| miR-200c, miR-141, miR-429, miR-203, miR-205 | Lower in MPM than lung adenocarcinoma | 115 MPM, 42 lung adenocarcinoma | (41) |
| miR-200c, miR-192 | Lower in MPM than other epithelioid tumours | 47 MPM, 259 carcinoma | (42) |
| miR-193a-3p | Higher in MPM than other epithelioid tumours | As above | (42) |
| miR-126, miR-143, miR-145, miR-652 | Lower in tumours than in normal tissue | 40 MPM, 12 DNB, 14 NNPa, 5 PTHX | (43) |
| miR-31 | Lower in tumours; higher in sarcomatoid tumours | 25 MPM, 20 RMP | (20) |
| miR-17-5p, miR-19b-3p, miR-625-5p | Lower expression associated with good prognosis (multivariate analysis) | 48 MPM | (44) |
| miR-31, miR-221, miR-222, miR-21, miR-23a, miR-30e | Signature—score positivity associate with good prognosis | 91 MPM (48 training, 43 test) | (44) |
| miR-103 | Lower in whole blood from MPM patients (in blood) | 23 MPM, 17 AEC, 25 HV | (45) |
| miR-126 | Lower in serum from MPM patients; Lower in serum from MPM patients compared with controls or NSCLC patients (in blood) | 44 MPM, 196 AEC, 50 HV; 44 MPM, 20 NSCLC, 56 HV | (46,47) |
| miR-625-3p | Increased in plasma from MPM patients (in blood) | 45 MPM, 24 controls | (48) |
| miR-34-b/c | Increased methylated promoter DNA in serum from MPM patients (in blood) | 48 MPM, 21 BAP, 41 HV | (49) |
a, adjacent normal tissue from MPM patients used in study. MPM, malignant pleural mesothelioma; RMP, reactive mesothelial proliferations; DNB, diagnostic biopsy; PTHX, pneumothorax; AEC, asbestos-exposed controls; BAP, benign asbestos pleurisy; HV, healthy volunteers, NSCLC, non-small cell lung cancer.